

Calprotectin Immunoassay

The first particle enhanced turbidimetric immunoassay (PETIA)
for quantitative analysis of total calprotectin in plasma.



Areas of use

- ➔ Diagnosis of inflammation
- ➔ Valuable addition to sepsis diagnosis¹⁻⁵

WE INNOVATE DIAGNOSTIC EFFICIENCY

CE marked
USA: Research use only

gentian

Gentian Calprotectin Immunoassay

Identifying systemic inflammatory responses

Plasma calprotectin accurately discriminates presence versus absence of systemic inflammation¹. Calprotectin levels are higher in plasma and serum in patients with sepsis and in patients admitted for postoperative care after major surgery than in patients admitted due to intoxication, suggesting that calprotectin levels are markedly increased in systemic inflammatory responses¹.

Gentian Calprotectin Immunoassay

A turbidimetric assay for measurement of calprotectin in plasma samples. The assay allows for rapid and flexible random access use and is an ideal solution for high throughput applications in the routine laboratory. Can be applied on all automated platforms, giving short turnaround time from sample to reportable result.

Areas of use

- Early biomarker of bacterial infections²
- In combination with CRP to identify sepsis vs postoperative inflammation¹
- Discriminate bacterial sepsis from viral infections³
- Diagnosis of rheumatoid arthritis⁶
- Diagnosis of appendicitis⁷
- Diagnosis of sclerosis⁸

Gentian Calprotectin Immunoassay Performance

Sample type	Li-Heparin plasma
Assay type	PETIA
Format	Liquid reagents, ready to use
Precision (sample 0.79 mg/L)*	Total CV 8.04%
Precision (sample 5.76 mg/L)*	Total CV 1.36%
LoQ*	≤ 0.31 mg/L
Security zone*	> 95 mg/L
Measuring range	0.5-20 mg/L
Calibration stability*	4 weeks ⁵

*Instrument dependent results achieved on Architect c4000 during validation.

⁵Reagent blank adjustment must be done every 3 days.

"Plasma calprotectin appears to be a useful early marker of bacterial infections in critically ill patients"

Jonsson et al²



WE INNOVATE DIAGNOSTIC EFFICIENCY

Contact information E-mail: marketing@gentian.com • www.gentian.com

References: 1. Simm, M., et al (2016). *Biomark Med* 10, 811-818 2. Jonsson, N., et al. (2017). *Crit Care Resusc* 19, 205-213 3. Bartáková, E. et al (2019). *Diagn Microbiol Infect Dis* 93, 219-226 4. Huang, L., et al (2016). *J Interferon Cytokine Res* 36, 607-616 5. Gao, S., et al (2015). *Am J Emerg Med* Sep 33, 1278-1282 6. Nordal, H. H., et al (2017). *Arthritis Res Ther* 19:3 doi: 10.1186/s13075-016-1201-07. Cikot, M., et al (2016) *World J Emerg Surg* 11:17 doi: 10.1186/s13017-016-0062-9 8. van Bon, L., et al (2014) *Ann Rheum Dis* 73:1585-1589

gentian